- United States
- /
- Medical Equipment
- /
- NasdaqGS:INGN
Chairman of the Board Heath Lukatch Just Bought Shares In Inogen, Inc. (NASDAQ:INGN)
Even if it's not a huge purchase, we think it was good to see that Heath Lukatch, the Chairman of the Board of Inogen, Inc. (NASDAQ:INGN) recently shelled out US$86k to buy stock, at US$43.01 per share. Even though that isn't a massive buy, it did increase their holding by 202.2%, which is a arguably a good sign.
Check out our latest analysis for Inogen
The Last 12 Months Of Insider Transactions At Inogen
Notably, that recent purchase by Heath Lukatch is the biggest insider purchase of Inogen shares that we've seen in the last year. So it's clear an insider wanted to buy, at around the current price, which is US$43.29. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. While we always like to see insider buying, it's less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. In this case we're pleased to report that the insider bought shares at close to current prices. The only individual insider to buy over the last year was Heath Lukatch.
The chart below shows insider transactions (by individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!
Insider Ownership of Inogen
Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Our data indicates that Inogen insiders own about US$9.0m worth of shares (which is 1.0% of the company). We do generally prefer see higher levels of insider ownership.
So What Do The Inogen Insider Transactions Indicate?
It is good to see the recent insider purchase. And an analysis of the transactions over the last year also gives us confidence. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Inogen insiders are expecting a bright future. Therefore, you should should definitely take a look at this FREE report showing analyst forecasts for Inogen.
Of course Inogen may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
About NasdaqGS:INGN
Inogen
A medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally.
Excellent balance sheet and fair value.
Similar Companies
Market Insights
Community Narratives
